Christine R Totri1, Lawrence F Eichenfield2, Kirsty Logan3, Laura Proudfoot3, Jochen Schmitt4, Irene Lara-Corrales5, Jeffrey Sugarman6, Wynnis Tom7, Elaine Siegfried8, Kelly Cordoro9, Amy S Paller10, Carsten Flohr3. 1. Department of Dermatology, SUNY Downstate Medical Center, Brooklyn, New York. 2. Division of Pediatric and Adolescent Dermatology, Rady Children's Hospital and University of California, San Diego, California. Electronic address: leichenfield@rchsd.org. 3. Unit for Population-Based Dermatology Research, St John's Institute of Dermatology, Guy's and St Thomas' Hospital NHS Foundation Trust and King's College London, London, UK. 4. Center for Evidence-based Healthcare, University Hospital Dresden and Institute for Occupational and Social Medicine, Technical University, Dresden, Germany. 5. Section of Dermatology, Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, Canada. 6. Department of Dermatology, University of California at San Francisco, San Francisco, California. 7. Division of Pediatric and Adolescent Dermatology, Rady Children's Hospital and University of California, San Diego, California. 8. Department of Pediatrics and Dermatology, Saint Louis University, Cardinal Glennon Children's Hospital, St Louis, Missouri. 9. Department of Pediatrics and Dermatology, University of California at San Francisco, San Francisco, California. 10. Department of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Abstract
BACKGROUND: There is a paucity of literature to direct physicians in the prescribing of immunomodulators for patients with severe atopic dermatitis (AD). OBJECTIVE: To survey systemic agent prescribing practices for severe childhood AD among clinicians in the United States and Canada. METHODS: The TREatment of severe Atopic dermatitis in children Taskforce (TREAT), US&CANADA, a project of the Pediatric Dermatology Research Alliance (PeDRA), developed an online multiple-response survey to assess clinical practice, gather demographic information and details of systemic agent selection, and identify barriers to their use in patients with recalcitrant pediatric AD. RESULTS: In total, 133 of 290 members (45.9%) of the Society for Pediatric Dermatology completed the survey, and 115 of 133 (86.5%) used systemic treatment for severe pediatric AD. First-line drugs of choice were cyclosporine (45.2%), methotrexate (29.6%), and mycophenolate mofetil (13.0%). The most commonly used second-line agents were methotrexate (31.3%) and mycophenolate mofetil (30.4%); azathioprine was the most commonly cited third-line agent. The main factors that discouraged use of systemic agents were side-effect profiles (82.6%) and perceived risks of long-term toxicity (81.7%). LIMITATIONS: Investigation of the sequence of systemic medications or combination systemic therapy was limited. Recall bias may have affected the results. CONCLUSION: Great variation exists in prescribing practices among American and Canadian physicians using systemic agents for treatment of pediatric AD.
BACKGROUND: There is a paucity of literature to direct physicians in the prescribing of immunomodulators for patients with severe atopic dermatitis (AD). OBJECTIVE: To survey systemic agent prescribing practices for severe childhood AD among clinicians in the United States and Canada. METHODS: The TREatment of severe Atopic dermatitis in children Taskforce (TREAT), US&CANADA, a project of the Pediatric Dermatology Research Alliance (PeDRA), developed an online multiple-response survey to assess clinical practice, gather demographic information and details of systemic agent selection, and identify barriers to their use in patients with recalcitrant pediatric AD. RESULTS: In total, 133 of 290 members (45.9%) of the Society for Pediatric Dermatology completed the survey, and 115 of 133 (86.5%) used systemic treatment for severe pediatric AD. First-line drugs of choice were cyclosporine (45.2%), methotrexate (29.6%), and mycophenolate mofetil (13.0%). The most commonly used second-line agents were methotrexate (31.3%) and mycophenolate mofetil (30.4%); azathioprine was the most commonly cited third-line agent. The main factors that discouraged use of systemic agents were side-effect profiles (82.6%) and perceived risks of long-term toxicity (81.7%). LIMITATIONS: Investigation of the sequence of systemic medications or combination systemic therapy was limited. Recall bias may have affected the results. CONCLUSION: Great variation exists in prescribing practices among American and Canadian physicians using systemic agents for treatment of pediatric AD.
Authors: F M Vermeulen; L A A Gerbens; A L Bosma; C J Apfelbacher; A D Irvine; B W M Arents; S Barbarot; M Deleuran; L F Eichenfield; A Manca; J Schmitt; C Vestergaard; D Wall; S Weidinger; M A Middelkamp-Hup; P I Spuls; C Flohr Journal: Br J Dermatol Date: 2019-06-23 Impact factor: 9.302
Authors: A M Drucker; K Eyerich; M S de Bruin-Weller; J P Thyssen; P I Spuls; A D Irvine; G Girolomoni; S Dhar; C Flohr; D F Murrell; A S Paller; E Guttman-Yassky Journal: Br J Dermatol Date: 2018-01-28 Impact factor: 9.302